+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are investigating whether regular radiological assessments during follow-up after surgery for high-risk malignant melanoma improve patient survival. The study addresses concerns about the resource demands, potential radiation exposure, and anxiety caused by such imaging, especially given the recent introduction of effective medical treatments for melanoma. There is currently no clear evidence supporting routine imaging in this context. Participants are randomly assigned to one of two groups. One group follows national guidelines with regular doctor appointments for 3 years, while the other group receives the same follow-up plus additional whole-body CT or PET scans and blood tests at baseline, 6, 12, 24, and 36 months. An interim analysis will be done after 1,000 patients enroll. During the study, researchers will monitor overall survival at 5 years as the primary outcome. They will also assess quality of life through questionnaires over the 3-year follow-up. Participants will attend scheduled visits for clinical evaluations, imaging, and blood tests, with the study aiming to provide clear evidence about the role of imaging in post-surgical melanoma care.

Age: 18Years +All GendersPhase Not Applicable
20 locations
E

Actively Recruiting

Researchers are studying patients who experience out-of-hospital cardiac arrest OHCA with ventricular fibrillation VF or ventricular tachycardia VT that do not respond to initial defibrillation. The study aims to evaluate whether using double sequential defibrillation DSD earlier, after the first failed standard defibrillation, can improve 30-day survival compared to continuing with standard defibrillation. This trial addresses important gaps in knowledge about optimal defibrillation strategies to increase survival in this critical condition. The trial compares two treatment groups one using early double sequential defibrillation, where a second defibrillator with pads placed in the anterior-posterior position is applied as soon as possible, delivering rapid sequential shocks from two devices and the other continuing with standard single defibrillation using one defibrillator with anterior-lateral pad placement. Both groups receive resuscitation until return of spontaneous circulation, resuscitation is stopped, or the patient is transported to the hospital. The study is randomized and open-label, involving ambulance units equipped with two study-specific defibrillators. Participants are adult OHCA patients with an initial shockable rhythm and at least one failed standard defibrillation. During the study, ambulance teams perform screening, randomization, treatment according to assigned group, and initial follow-up. The main outcome measured is survival at 30 days. Secondary outcomes include return of spontaneous circulation, survival to hospital admission and discharge, and neurological function at discharge. The study will continue monitoring these outcomes to assess the effectiveness of early DSD compared to standard defibrillation strategies.

Age: 18Years +All GendersPhase 2Phase 3
14 locations
P

Actively Recruiting

Healthy Volunteer

Gestational diabetes mellitus GDM is a common metabolic problem during pregnancy, affecting 2-10% of pregnant women in Sweden depending on screening methods. Women with GDM face about a 50% chance of developing type 2 diabetes T2DM within 20 years. This research evaluates a lifestyle intervention model using both personal and technical support to help prevent T2DM after pregnancy, aiming for an inexpensive and easy-to-implement approach within regular primary care. Participants will be randomly assigned to receive either the lifestyle intervention or usual care. The intervention includes support at every visit to the Child Health Care Centre with blood tests, measurements, and guidance on diet and physical activity. Participants also get access to a digital platform called MyMOWO, which offers personalized exercise programs and health coaching. Women in the usual care group continue with standard follow-up at health care units. A control group of women with normal glucose tolerance will also be studied. Throughout the study, women will have physical examinations, blood tests including oral glucose tolerance tests, questionnaires on lifestyle and diet, and fitness tests like VO2max. Measurements will take place at baseline, one year, 18 months, four years, and five years after delivery. Data on insulin resistance, blood sugar control, fitness, wellbeing, and glucose tolerance will be collected. Women who become pregnant again during the study will be excluded from final analysis but encouraged to stay involved. The total participation duration is up to five years, with ongoing monitoring and support.

Age: 18Years - 60YearsFEMALEPhase Not Applicable
1 location
G

Actively Recruiting

Healthy Volunteer

Researchers are investigating whether reducing wheat gluten or certain amino acids commonly found in wheat gluten can improve blood sugar control and reduce inflammation in healthy volunteers, parents, children, adolescents, and adults, including those with diabetes. The study also seeks to identify individuals who have an inflammatory response leading to poor blood sugar control. It explores the connections between diabetes, inflammation, and severe COVID-19 infection. Participants will follow a diet with four different phases over four weeks their usual diet, a gluten-free diet, a diet containing wheat gluten, and a diet including gluten combined with probiotics. During these periods, participants will consume gluten-free or regular gluten-containing pasta meals and take probiotics as described. The study uses a crossover design where each participant serves as their own control. Continuous glucose monitors and activity trackers will be used to assess glucose uptake during the study. Participants will attend four clinical visits at baseline and weekly intervals for blood sampling. They will also collect samples at home, including capillary blood, feces, urine, buccal swabs, and saliva, and complete questionnaires about diet, diabetes risk factors, and COVID-19. The main outcomes include stabilizing blood sugar levels and amino acid metabolism. Secondary outcomes include blood lipids, glutathione S transferases, and fibrinogen. Total study duration for each participant is four weeks.

Age: 6Years +All GendersPhase Not Applicable
2 locations
H

Actively Recruiting

This research aims to determine if hip replacement surgery arthroplasty can reduce the need for additional operations compared to internal fixation in elderly patients with an undisplaced femoral neck fracture. Patients aged 75 years and older with this type of fracture will be included and randomly assigned to one of two treatments through the Swedish Fracture Register platform. The study focuses on combining reoperation rates and mortality into a single main outcome measure to evaluate which treatment offers better results. Participants will receive either arthroplasty, which may be hemi or total hip replacement depending on the patients condition and surgeons decision, or internal fixation using screws, pins, or a sliding hip screw device based on hospital routine. The study is a randomized controlled trial without blinding, comparing these two device-based treatments for hip fractures in elderly patients. During the study, researchers will monitor the combined rate of reoperations and mortality for 1 to 2 years after surgery. Additional outcomes include reoperation rates, short- and long-term mortality, and patient-reported physical function one year after surgery. Participants will be followed up to assess these outcomes, with care taken to track their progress and safety over the study period.

Age: 75Years +All GendersPhase Not Applicable
25 locations
S

Actively Recruiting

Spontaneous intracerebral hemorrhage ICH is a serious type of stroke with high death and disability rates. Researchers are investigating whether a structured treatment package called a Care Bundle can improve the 3-month outcomes for patients with acute ICH compared to standard care. The study is an international, multicenter, parallel, cluster-randomized clinical trial focusing on implementing this Care Bundle in high-income countries, building on results from previous trials mostly done in low- and middle-income countries. The Care Bundle includes early intensive blood pressure lowering, treatment of fever and high blood sugar, rapid reversal of oral anticoagulation, and timely referrals to intensive care or neurosurgery when needed. Hospitals are randomized in batches through three phases usual care, randomized evaluation of the Care Bundle versus usual care, and a post-implementation follow-up where all hospitals apply the Care Bundle. Each batch lasts 18 months, with 6 months per phase, and the overall study rollout spans 2.5 years. Participants are adults aged 18 or older diagnosed with spontaneous ICH confirmed by imaging within 24 hours of symptom onset. During the study, patient management details and outcomes will be closely monitored, including brain imaging, blood pressure, glucose levels, and functional status. The primary outcome is functional recovery measured by a utility-weighted modified Rankin Scale score at 180 days. Secondary outcomes include disability, death, and health-related quality of life. The study also collects data on treatments and care decisions to evaluate the Care Bundles effectiveness and sustainability.

Age: 18Years +All GendersPhase 4
54 locations
T

Actively Recruiting

Preterm preeclampsia is a serious condition affecting both mothers and their babies, often leading to early delivery to protect health. This trial is investigating whether metformin, a common diabetes medication, can safely delay delivery, reduce the time newborns spend in intensive care, and increase birthweight in a Nordic population. The study builds on prior research suggesting metformin may modify disease progression and improve outcomes for preterm preeclampsia. Participants will be randomly assigned to receive either extended-release metformin tablets, starting with 500 mg three times daily and potentially increasing to 1 gram three times daily as tolerated, or placebo tablets with the same dosing schedule. Treatment continues until delivery. Participants will keep a diary to track medication adherence, and standard care for preeclampsia will continue alongside the study treatment. During the study, participants will be monitored from randomization until delivery to measure how long pregnancy is prolonged. After birth, researchers will track how long newborns require neonatal care and record birthweight. Follow-up assessments of mothers and children will occur two years after birth. The total participation period varies depending on delivery timing, with data collection focusing on pregnancy duration and neonatal outcomes.

Age: 18Years +FEMALEPhase 3
18 locations
L

Actively Recruiting

Researchers are evaluating the long-term reliability and performance of cardiac rhythm products marketed by Medtronic. This observational study focuses on devices such as leads, implantable pulse generators, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices used for conditions like arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study aims to analyze product survival probabilities and monitor lead-related complications over time. Participants include individuals who have received or will receive Medtronic market-released cardiac devices for pacing, sensing, or defibrillation. The study includes products implanted as part of routine care or participants from prior qualifying studies. Data is collected from the time of implantation and continues until the device is removed from service, the patient exits the study, or passes away. Enrollment criteria also require consent for access to health information. During the study, participants device performance is monitored through follow-up data collection. Researchers assess complications related to the implanted leads and track device status over long periods, potentially spanning several years. The study does not involve additional treatments but relies on routine clinical follow-up and health information review. The total duration extends up to December 2040, allowing comprehensive long-term evaluation of device performance.

All AgesAll Genders
338 locations
S

Actively Recruiting

This research aims to evaluate whether specific abdominal muscle exercises can reduce the risk of developing parastomal hernias in patients receiving a permanent sigmoidostomy after surgery for colon cancer. Parastomal hernias affect about half of these patients and can significantly impact stoma function, physical ability, and quality of life. The study also explores patients experiences living with parastomal hernias to better understand daily challenges. Participants will be randomly assigned to one of two groups one group will receive usual care advice to prevent hernias, while the other will receive the same advice plus specific abdominal muscle training. This training starts before surgery and continues for the first year afterward. The study includes clinical assessments, manual and electronic measurements of hernia size, and computed tomography CT scans to track hernia development at 6, 12, and 36 months post-surgery. Throughout the study, participants will report on stoma function, discomfort, and quality of life using tailored questionnaires. Researchers will record the type of ostomy bandage used and assess physical activity and back pain from before surgery up to 36 months afterward. A subgroup will participate in interviews to share their experiences living with hernias. The studys results aim to improve methods for assessing hernias and inform future patient care after stoma surgery.

All AgesAll GendersPhase Not Applicable
4 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of apixaban as a stroke prevention treatment in adults with stage 5 chronic kidney disease CKD who also have atrial fibrillation AF or atrial flutter AFL. This study compares apixaban to no anticoagulation to see if it reduces the risk of ischemic stroke without increasing fatal or brain bleeding events. The trial also examines all-cause mortality, cardiovascular events, and major bleeding risks in this patient group. Participants are randomly assigned to one of two groups one receiving apixaban 2.5 mg twice daily plus standard care, and the other receiving standard care without anticoagulation. The study is open-label and conducted over 12 to 72 months across around 50 sites in several European countries. Patients already on warfarin, apixaban, or low molecular weight heparin may join after stopping their current anticoagulation. Routine blood tests are done at inclusion. During the trial, participants will be monitored for ischemic stroke, intracranial or fatal bleeding, death, cardiovascular events, and major bleeding according to established criteria. Additional outcomes include thromboembolic events and kidney transplant-related complications. The study lasts up to 72 months per participant or until a set number of events occur. Safety and efficacy data are reviewed by independent boards throughout the study.

Age: 18Years +All GendersPhase 3
34 locations

1-10 of 16

1